Investors & Media Company Overview UNITY Biotechnology is developing therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating medicines that target cellular senescence and aging-related biology in ophthalmologic and neurologic diseases, while leveraging partnerships in growth areas with high unmet need. Stock Information Data Provided by Refinitiv. Minimum 15 minutes delayed. Latest Presentation Download News Releases July 23, 2021 UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease July 6, 2021 UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
July 23, 2021 UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
July 6, 2021 UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
